MiMedx Group (MDXG) investor relations material

Business overview and market opportunity

• Focuses on wound and surgical healing solutions, addressing a large and growing patient population with chronic wounds, especially among Medicare beneficiaries.

• Products primarily derived from birth tissue, with a vertically integrated supply chain and proprietary processing technology.

• Two-thirds of revenue comes from wound care, one-third from surgical applications, both segments growing.

• Direct sales force covers a wide range of care settings, with supplemental agents as needed.

• Leadership team has deep med tech experience, driving strategic priorities for growth and value creation.

Regulatory and reimbursement environment

• Recent CMS changes to reimbursement structure, moving to a flat price per square centimeter and application fee, are viewed positively.

• Supportive of CMS's new methodology, with minor tweaks suggested in upcoming comments.

• Preparing for new rules by expanding product offerings and readying manufacturing to scale as needed.

• Anticipates patient migration from private offices to wound care centers due to reimbursement changes.

Product innovation and pipeline

• Launching Epi Express later this year, a fenestrated sheet designed for improved fluid retention in wound care.

• Robust R&D pipeline focused on both internal development and external partnerships or acquisitions, especially in xenograft and synthetic technologies.

• Strategic alliance with Vaprox adds complementary adjunctive therapy, enabling earlier patient engagement in the wound care continuum.

• Ongoing clinical evidence generation, including EpiFACT RCT, to support product adoption and reimbursement.